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Abstract
The discovery of new classes of antibacterial agents, particularly those with unique biological 
targets, is essential to keep pace with emerging drug resistance in pathogenic bacteria. We 
identified the minimal structural component of the cyclic acyldepsipeptide (ADEP) antibiotics that 
exhibits antibacterial activity. We found that N-acyldifluorophenylalanine fragments function via 
the same mechanism of action as ADEPs, as evidenced by the requirement of ClpP for the 
fragments’ antibacterial activity, the ability of fragments to activate B. subtilis ClpP in vitro, and 
the capacity of an N-acyldifluorophenylalanine affinity matrix to capture ClpP from B. subtilis cell 
lysates. N-acyldifluorophenylalanine fragments are much simpler in structure than the full ADEPs 
and are also highly amenable to structural diversification. Thus, the stage has been set for the 
development of non-peptide activators of ClpP that can be used as antibacterial agents.
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Recently, the cyclic acyldepsipeptide (ADEP) antibiotics have garnered considerable 
attention because of their potent antibacterial activity against a broad range of Gram-positive 
bacterial pathogens and their efficacy in animal models of bacterial infection.[1] The cellular 
target of the ADEPs is ClpP, a component of the highly conserved Clp proteolytic 
complexes in bacteria.[1c, 2] ClpP is a self-compartmentalized, tetradecameric serine 
peptidase that functions in conjunction with accessory AAA+ partners (ATPases associated 
with diverse cellular activities), which themselves play important roles in substrate 
recognition and regulation of ClpP proteolytic activity.[2d, 3] Clp proteolytic complexes 
degrade a variety of misfolded and native target proteins, including those involved 
regulating stress responses and virulence-factor production.[4] ADEPs bind ClpP and 
dysregulate its activity by opening its axial pores, yielding a peptidase that indiscriminately 
degrades large peptides and unstructured proteins without the involvement of AAA+ 
partners, ultimately leading to inhibition of cell division and cell death.[1c, 2a]
In crystal structures of the B. subtilis ClpP tetradecamer in complex with ADEPs, the small 
molecules bind with exquisite specificity at the intra-subunit sites to which AAA+ partners, 
like ClpX and ClpA, also bind.[2b, 2c, 5] Intriguingly, it has been proposed that the N-
acylphenylalanine side chain appended to the ADEP peptidolactone mimics the highly 
conserved IGF or LGF tripeptide motifs of ClpX and ClpA that mediate interactions with 
ClpP.[2b, 5] We find this proposal to be thought-provoking in light of our recent finding that 
rigidification of the peptidolactone via incorporation of conformationally constrained amino 
acids can improve ClpP activation in vitro by as much as 7-fold.[6] These observations 
motivated us to carry out experiments to define the relative contributions of the ADEP 
peptidolactone and its side chain to ClpP binding and activation.
For this analysis, we prepared fragments of the ADEP structure (1) including an ADEP 
peptidolactone with an N-acetylated serine residue (2), an N-acetyldifluorophenylalanyl 
peptidolactone (3), a serine-prolyl ester coupled to N -E-2-heptenoyldifluoro-phenylalanine 
(4), and an N-E-2-heptenoyldifluorophenylalanine methyl ester (5) (Figure 1). The 
bioactivities of the fragments were assessed in growth inhibition assays using wild-type B. 
subtilis AG174, a highly ADEP-susceptible bacterium. Only, fragments 4 and 5 exhibited 
antibacterial activity, albeit with much lower potency than intact ADEP (Figure 1). Clearly, 
the N-acyldifluorophenylalanine moiety is necessary and sufficient for antibacterial activity. 
Interestingly, fragment 4, which has an acyclic portion of the ADEP peptidolactone, is less 
active than fragment 5, which is composed only of the N-acyldifluorophenylalanine moiety.
Based on our recent report that conformational flexibility of the ADEP peptidolactones 
strongly influences ClpP binding,[6] we predicted that substitution of the serine in 4 with 
either allo-threonine (6) or threonine (7) (Figure 2) would yield more rigid and bioactive 
fragments. However, both compounds exhibited the same antibacterial activity as fragment 4 
(MIC = 32 μg/mL), suggesting that the allo-threonine and threonine residues do not 
significantly or favorably restrict the conformations of the acyclic fragments.
A positional scanning approach was used to define the minimal structural requirements for 
the bioactivity of fragment 5. First, we synthesized analogs with varied acyl chains (8-10; 
Figure 2). Fragment 8 bears an acyl chain that is common to previously reported synthetic 
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ADEPs[1c] and fragment 9 bears the acyl chain of the A54556 ADEP natural products.[1a] 
Fragment 10 is an analog that we synthesized to test the effects of acyl group carbon-
branching. Fragments 5, 8, and 10 were equally potent (MIC = 8 μg/mL), whereas fragment 
9 exhibited attenuated activity (MIC = 32 μg/mL). This result is consistent with the 
literature, wherein analogs with polyunsaturated side chains are reportedly less active 
compared to analogs with α,β-unsaturation.[1d] Fragments 11 and 12 (Figure 2) with 
saturated acyl groups had reduced antibacterial activity like their ADEP counterparts.[1d] We 
next studied a pair of analogs in which the difluorophenylalanine was replaced by either 
phenylalanine (13) or leucine (14). The relatively modest activity of the fragment with the 
phenylalanine residue (13, MIC = 64 μg/mL) is consistent with the proposal that the fluorine 
atoms of difluorophenylalnine are engaged in hydrogen bonds with backbone amides of 
ClpP.[1d] In contrast, the analog containing leucine (14) was completely inactive. 
Collectively, the results are consistent with published studies of ADEP structure activity 
relationships.[1d]
Next, we explored the effects of several C-terminal manipulations on the antibacterial 
activity of fragment 5. Interestingly, the methyl ester (5) was more potent that than either the 
carboxylic acid or amide analogs thereof (15-18). The low potencies of the carboxamides 
were surprising, because the N-acyldifluorophenylalanine moiety in the ADEPs is linked to 
the peptidolactone via an amide bond. In any case, three additional ester analogs (19-21) 
were prepared. Only the propargyl ester 21 (MIC = 2 μg/mL) was more potent than 5. The 
potency of the intact ADEPs and the findings that modification of the carboxy-terminus of 5 
can improve potency suggest that the structural context in which the bioactive N-
acyldifluorophenylalanine moiety is presented is important and can be optimized.
We tested our operating assumption that ADEPs and N-acyldifluorophenylalanine fragments 
have the same mechanism of killing bacteria in a series of genetic and biochemical 
experiments. In initial genetic experiments, an ADEP (1) and fragments 4 and 5 were tested 
for antibacterial activity against two engineered strains of B. subtilis- a spx null strain (AG 
1927 spx::neo) and a strain lacking both spx and clpP (AG 1246 spx::neo and clpP::cat).[7] 
The clpP-spx null strain was selected because the spx null mutation suppresses the slow 
growth defect exhibited by a B. subtilis strain lacking clpP.[7] The spx null and wild-type 
strains of B. subtilis, both of which contain a functional ClpP, were equally susceptible to 
each of the three compounds. Importantly, neither intact ADEP nor fragments 4 and 5 were 
toxic to the spx-clpP null strain (MIC > 128 μg/mL). The essentiality of a functional clpP 
gene for the toxicity of both compounds indicates that the fragments share the same 
mechanism as the ADEPs.
We also tested for cross-resistance by selecting for spontaneously resistant mutants to either 
1 or 5 in the spx null strain. Mutants with resistance to the intact ADEP and fragment 5 were 
observed at frequencies of 3 × 10−6 colony forming units (cfu) and 7 × 10−5 cfu, 
respectively. As expected, all mutants resistant to 1 were resistant to 5 and vice-versa (MICs 
>300 μg/mL). By sequencing the clpP locus in the mutants, we determined that resistance 
was highly correlated with mutations in the promoter of the clpP gene or with mis-sense or 
frameshift mutations in the clpP open-reading frame (see supporting information).
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To biochemically validate the proposal that ADEP fragments activate ClpP peptidase 
activity, they were tested for activation of B. subtilis ClpP in vitro (Figure 3; Figure S2). 
Fragments were incubated with B. subtilis ClpP and a fluorogenic decapeptide and initial 
rates of ClpP mediated decapeptide hydrolysis were measured. All fragments exhibited 
concentration-dependent activation of ClpP decapeptidase activity and exhibited apparent 
activation constants (Kapp) ranging from 3.9 – 7.9 μM. Since the binding affinities fall into 
a narrow range, the large differences in bioactvities of the compounds can be primarily 
atributed to their in vivo stability and/or cell-permeability. Nevertheless, the fragment with 
the most potent antibacterial activity (21) was also the tightest ClpP binder. In any case, 
fragment binding to and activation of ClpP were much weaker than those of ADEP (1) (Kapp 
= 12 nM, Hill coefficient 2.02±0.08). However, the ADEP (1) and all fragments tested 
exhibited modest positive cooperativity in ClpP binding (i.e., Hill coefficients >1), 
suggesting that the ADEP and fragments bind in the same general fashion.
To complement our finding that fragments activate ClpP in vitro, we used chemical 
proteomics experiments utilizing fragment-derived, affinity reagent.[8] The N-
acyldifluorophenylalanine propargyl ester (21) was coupled to a biotin-azide conjugate via a 
Cu(I)-catalyzed Click reaction.[9] After the binding to avidin– agarose beads, the resulting 
affinity matrix was used to capture proteins from cell lysates of the wild-type and the clpP-
spx null strain of B. subtilis. The specifically bound proteins were eluted using free fragment 
5 and identified using MASCOT proteomic analysis. We were gratified to find ClpP among 
the thirty-nine unique and functionally annotated proteins that were positively identified 
(Table 2, supporting information). Interestingly, 20 of these proteins were also captured 
from the lysates of the clpP-spx null strain. The biological significance of these off-target 
binding events is not clear, as compound 14 and other fragments have no effect the growth 
of the clpP-spx null strain (i.e., the compounds’ bioactivity is dependent on ClpP). A 
speculative explanation for the off-target binding of the eighteen unique proteins in the 
lysates of the wild-type strain is that some of them are ClpP substrates (or degradation 
products thereof) that were trapped within the captured tetradecamer.[15]
In conclusion, a truly remarkable example of perturbation of protein-protein interactions by 
a small molecule underlies the antibacterial activities of the ADEPs. Their binding to ClpP 
induces significant changes in the quaternary structure[2b, 2c] of the enzyme, which enhance 
off-target activity and precludes interaction with AAA+ partners.[2a] It has been proposed 
that binding and activation of ClpP are predicated on the mimicry of IGF and LGF motifs of 
the AAA+ partners by the ADEP side chain. Here, we report that only the N-
acyldifluorophenylalanine moiety of the ADEPs is required for their bioactivities. These 
results are especially notable in light of reports that an IGF tripeptide alone does not activate 
ClpP or interfere with the binding of ClpP to ClpX.[11] We believe that the essentiality of the 
N-acyldifluorophenylalanine moiety for both ClpP activation and antibacterial activity can 
be reconciled with our recently reported finding that restriction of the peptidolactone 
dyanamics improves activity. Specifically, the strengthened trans-annular hydrogen bonding 
between the macrocycle and the side chain could enhance cell-permeability and lock the side 
chain in a conformation for optimized ClpP binding.
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Our definition of the ADEPs’ simple pharmacophore has important implications. Firstly, the 
ease of fragment synthesis, relative to the ADEPs, makes ClpP activators more accessible to 
the growing number of groups interested in their mechanism of killing bacteria. In addition, 
the reported fragments are generally stable and can be stored at room temperature for weeks 
without any detectable degradation with two exceptions (9: light sensitive; 19: acid 
sensitive). Secondly, our findings provide a starting point for fragment-based design of non-
peptide activators of ClpP. In this ligand-design strategy, weakly active fragments are 
structurally elaborated into higher affinity ligands. [12] Although fragment-based drug design 
is a relatively new, it has become widely appreciated as a powerful tool in drug 
discovery.[12d–f] The fragment-based design strategy is a viable alternative to screening 
libraries of compounds in the search for non-peptide ClpP activators.[13] Such efforts are 
motivated by concerns that the ADEP peptidolactone backbone could have pharmacological 
liabilities that are often associated with peptides, [14] despite the fact that structurally 
optimized ADEPs effectively cure bacterial infections in mice and rats.[1c, 1d, 1g] 
Conveniently, the N-acyldifluorophenylalanine moiety is highly amenable to structural 
elaboration as it possesses a reactive carboxylate functionality that can be easily coupled to a 
wide array of scaffolds and rapidly diversified. Work to develop more potent antibacterial 
agents using this strategy is underway in these laboratories.
Experimental Section
Experimental procedures for the preparation of chemical compounds, antibacterial assays, 
ClpP activation assays, ClpP mutant selection, and chemical proteomics are described in the 
supporting information
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Fragments of a cyclic acyldepsipeptide have differential antibacterial activity against B. 
subtilis.
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Figure 2. 
Structures and antibacterial activities of N-acyldifluorophenylalanine fragment analogs 
against B. subtilis.
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Figure 3. 
ClpP binding of key N-acyldifluorophenylalanine fragment analogs. Hydrolysis of a 
fluorogenic decapeptide substrate (15 μM) by B. subtilis ClpP (25 nM) was assayed in the 
presence of increasing concentrations of ADEP fragments, and activity was fit to a 
cooperative binding model (Figure S2) to determine apparent binding constants (Kapp) and 
Hill Coefficients.
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Table 1
Compound ClpP Kapp (μM) Hill Coefficient
4 6.4±0.1 1.4±0.04
5 6.3±0.2 1.6±0.07
6 7.9±0.4 1.5±0.08
7 11±0.3 1.6±0.06
8 7.3±0.3 1.2±0.05
21 3.9±0.1 1.6±0.04
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Table 2
Affinity Captured Proteins from B. subtilis Lystates Encoded by Functionally Annotated Genes
2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylate synthase* DnaB* MinC*
3-ketoacyl-ACP reductase* DnaI RapJ
Alpha-galactosidase Fengycin synthetase* Ribosomal protein B*
Aminoglycoside 6-adenylyltransferase Flagellar switch protein* RNA polymerase sigma-54 factor*
AnsB Formamidopyrimidie-DNA glycosidase* SHCHC synthase*
Aspartokinase II alpha subunit Fructose-1-phosphate kinase SinR
ATP-dependent nuclease GerC3* Spore coat protein
Bacillomycin synthetase A* GltC* SpoVS
Cell division ATP-binding protein* Gluconate kinase* SrfAA surfactin synthetase
Chemotaxis protein Gramicidin S sythetase* SubA
ClpP Heptaprenyl diphosphate synthase* Sucrase
Deoxyribodipyrimidine photolyase* L-aspartase Superoxide dismutase
DNA polymerase I* Lysine decarboxylase* TreP
[a] Thirty-nine functionally annotated proteins positively identified by MASCOT Proteomic Analysis as specifically bound to N-E-2-
heptenoyldifluoro-phenylalanine affinity matrix. See supporting information for a complete protein list. Proteins captured from both WT and the 
clpP null strain of B. subtillis are indicated by asterisks. ClpP is highlighted in bold text.
Chembiochem. Author manuscript; available in PMC 2015 October 13.
